Boxed Warnings Added to Drug for Ulcerative Colitis, Arthritis

Tofacitinib (Xeljanz) now carries boxed warnings about increased risks for thrombosis and death in patients taking higher doses of the drug, the FDA said on...

By the Editors

Tofacitinib (Xeljanz) now carries boxed warnings about increased risks for thrombosis and death in patients taking higher doses of the drug, the FDA said on Friday. The oral Janus kinase inhibitor is approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Comment

LINK(S):

FDA's MedWatch safety alert (Free)

FDA's drug safety communication (Free)

Updated tofacitinib prescribing information (Free)

Background: Physician's First Watch coverage of earlier FDA warning on tofacitinib in rheumatoid arthritis (Free)